Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant ...

New York, United States , April 04, 2023 (GLOBE NEWSWIRE) -- The Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Size is expected to grow from USD 1.6 Billion in 2021 to USD 38.90 Billion ...

A protein called isocitrate dehydrogenase (IDH1) is present at high levels in lung cancers and can be detected in the blood, making it a noninvasive diagnostic marker for lung cancers. A protein ...

Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for vorasidenib for the treatment of isocitrate dehydrogenase- (IDH)-mutant diffuse glioma.

Servier India announced the launch of Ivosidenib (Tibsovo®), a targeted therapy for Acute Myeloid Leukemia (AML) and ...

Learn more about Servier's leadership in mutant IDH inhibition at ASH booth #1347 BOSTON, Dec. 9, 2023 /PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow ...

Vorasidenib becomes the first targeted therapy for grade 2 isocitrate dehydrogenase (IDH)–mutant glioma to receive FDA approval. "Today's approval of Voranigo is an enormous leap forward in ...

Servier India, a subsidiary of the leading French pharmaceutical Servier Group, has announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer ...